The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Anti-PD-1 antibody combined with albumin-bound paclitaxel and gemcitabine (AG) as first-line therapy and Anti-PD-1 monotherapy as maintenance in metastatic pancreatic ductal adenocarcinoma (PDAC).
 
Jiujie Cui
Research Funding - Jiangsu Hengrui Medicine
 
Haiyan Yang
Research Funding - Jiangsu Hengrui Medicine
 
Jiong Hu
Research Funding - Jiangsu Hengrui Medicine
 
Jiayu Yao
Research Funding - Jiangsu Hengrui Medicine
 
Yu Wang
Research Funding - Jiangsu Hengrui Medicine
 
Yiyi Liang
Research Funding - Jiangsu Hengrui Medicine
 
Yongchao Wang
Research Funding - Jiangsu Hengrui Medicine
 
Feng Jiao
Research Funding - Jiangsu Hengrui Medicine
 
Xiaofei Zhang
Research Funding - Jiangsu Hengrui Medicine
 
Xiao Zhang
Research Funding - Jiangsu Hengrui Medicine
 
Ting Han
Research Funding - Jiangsu Hengrui Medicine
 
Tiebo Mao
Research Funding - Jiangsu Hengrui Medicine
 
Qing Xia
Research Funding - Jiangsu Hengrui Medicine
 
Xiuying Xiao
Research Funding - Jiangsu Hengrui Medicine
 
Li-Wei Wang
Speakers' Bureau - ASD; Hengrui Medicine; Merck
Travel, Accommodations, Expenses - Roche